Literature DB >> 33268698

Knockdown of long non-coding RNA LINC00473 protects CHON-001 cells against interleukin-1β-induced cell injury.

Dijun Ou1, Wenbin Ding1, Changjun Tong1, Weihong Yi1.   

Abstract

Osteoarthritis is a chronic joint disease with high prevalence. However, effective treatment options for OA are still lacking. It was previously reported that LINC00473 was upregulated in patients with OA and upregulated LINC00473 might associated with the progression of OA; however, the role of LINC00473 in OA remains to be investigated. CHON-001 human chondrocyte cells stimulated with 10 ng/ml IL-1β were utilized to mimic OA in vitro. Protein expression, cell apoptosis and cell proliferation of CHON-001 cells were investigated by western blot, Annexin V and PI double staining, cell counting-8 kit assay and immunofluorescence staining respectively. The result indicated IL-1β triggered viability decrease and apoptosis in CHON-001 cells, which was alleviated by LINC00473 knockdown. Meanwhile, IL-1β-induced upregulation of cleaved caspase 3 and Bax were ameliorated by LINC00473 knockdown. Likewise, IL-1β-induced downregulation of XIAP was alleviated by LINC00473 knockdown. In addition, LINC00473 knockdown protected CHON-001 cells against IL-1β by inhibiting the methylation of LIM mineralization protein-1 (LMP)-1 gene. Moreover, JNK/NF-κB signaling pathway was proved to be involved in the cell protective effect of LINC00473 knockdown in IL-1β treated CHON-001 cells. Taken together, LINC00473 knockdown defended CHON-001 cells from IL-1β induced cell injury via inhibition of the methylation of LMP-1. Thus, LINC00473 might possibly act as a novel therapeutic target for OA.

Entities:  

Keywords:  LIM mineralization protein-1; LINC00473; NF-κB; Osteoarthritis

Year:  2020        PMID: 33268698     DOI: 10.1248/bpb.b20-00688

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  1 in total

1.  LIM mineralization protein-1 inhibits IL-1β-induced human chondrocytes injury by altering the NF-κB and MAPK/JNK pathways.

Authors:  Dijun Ou; Sheng Liu; Changjun Tong; Hezhong Tan; Yadong Yang; Chunlei He
Journal:  Exp Ther Med       Date:  2021-11-21       Impact factor: 2.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.